PMID: 16644609Apr 29, 2006Paper

Efficacy and safety of prednisolone in patients with autoimmune hepatitis

Advances in Therapy
Keiichiro YoneyamaMichio Inawari

Abstract

A retrospective cohort study involving 29 Japanese patients with autoimmune hepatitis (AIH) was performed to clarify factors that predict the efficacy of prednisolone and the occurrence of various serious adverse effects. Independent predictors were identified by logistic analysis and with use of the Cox proportional hazard model. Responses to prednisolone were noted in 28 patients, who were classified into the complete remission group (52%) or the relapse group (48%). Multivariate analysis identified alanine aminotransferase, alkaline phosphatase, and immoglobulin G levels as independent predictors of relapse. The adverse effects most frequently observed were diabetes mellitus (37.9%), psychiatric/ neurologic symptoms (34.5%), and circulatory symptoms (34.5%). Predictive factors included lactate dehydrogenase, albumin, and fasting blood glucose levels for diabetes mellitus, alkaline phosphatase and C-reactive protein for psychiatric/ neurologic symptoms, and autoimmune hepatitis score and lactate dehydrogenase for circulatory symptoms. Selection of an optimal treatment method for individual patients may be possible after the risks of relapse and adverse effects have been estimated.

References

Apr 1, 1988·Clinical Pharmacology and Therapeutics·A E StuckF J Frey
Jun 30, 1965·Annals of the New York Academy of Sciences·I R MackayJ Hasker
Sep 1, 1983·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J E HegartyR Williams
Mar 1, 1983·Scandinavian Journal of Gastroenterology·H BergremA Bergan
Mar 1, 1993·Gastroenterologia Japonica·M OnjiY Ohta
Feb 1, 1995·Digestive Diseases and Sciences·A J Czaja
May 1, 1993·Journal of Gastroenterology and Hepatology·K KajinoB Matsuura
Oct 1, 1993·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P J Johnson, I G McFarlane
Apr 4, 1996·The New England Journal of Medicine·E L Krawitt
Feb 24, 2001·Internal Medicine·G Toda
Mar 27, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Albert J CzajaHerschel A Carpenter
Jul 27, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Albert J CzajaUNKNOWN American Association for the Study of Liver Disease
Mar 26, 2003·Liver International : Official Journal of the International Association for the Study of the Liver·Albert J Czaja, Herschel A Carpenter
May 1, 1959·The Journal of Endocrinology·A VERMEULEN
May 15, 1965·American Journal of Obstetrics and Gynecology·W R BLACKBURND G MCKAY
Sep 25, 2004·Digestive Diseases and Sciences·Keiichiro YoneyamaKeiji Mitamura
Feb 4, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Albert J CzajaMikio Zeniya
Mar 4, 2005·Scandinavian Journal of Gastroenterology·K YoneyamaK Mitamura

❮ Previous
Next ❯

Citations

Feb 14, 2008·Expert Opinion on Therapeutic Targets·Ming-Hua ZhengYong-Ping Chen
Apr 19, 2016·Internal Medicine·Naoki MatsumotoMitsuhiko Moriyama
Apr 7, 2007·Current Opinion in Gastroenterology·Albert J Czaja
May 9, 2008·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Teru KumagiJenny Heathcote
Jun 26, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Keith D LindorUNKNOWN American Association for Study of Liver Diseases
May 4, 2013·Expert Review of Gastroenterology & Hepatology·Albert J Czaja
Sep 10, 2013·Alimentary Pharmacology & Therapeutics·K ZachouL Muratori

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Hepatitis

Autoimmune hepatitis formerly called lupoid hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells causing the liver to be inflamed. Discover the latest research on autoimmune hepatitis here.